Get the Stockscreener App
16.68
0.97%
0.16
Janux Therapeutics Inc stock is traded at $16.68, with a volume of 1.30M.
It is up +0.97% in the last 24 hours and down -10.32% over the past month.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
See More
Previous Close:
$16.52
Open:
$16.42
24h Volume:
1.30M
Relative Volume:
1.28
Market Cap:
$1.02B
Revenue:
$13.73M
Net Income/Loss:
$-114.48M
P/E Ratio:
-9.0564
EPS:
-1.8418
Net Cash Flow:
$-78.49M
1W Performance:
-1.07%
1M Performance:
-10.32%
6M Performance:
+23.01%
1Y Performance:
-26.97%
1-Day Range:
$15.75
$16.79
1-Week Range:
$15.75
$17.47
52-Week Range:
$12.12
$35.34
Janux Therapeutics Inc Stock (JANX) Company Profile
Name
Janux Therapeutics Inc
Sector
Industry
Phone
(858) 751-4493
Address
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Compare JANX vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
16.68 | 1.02B | 13.73M | -114.48M | -78.49M | -1.8418 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-24-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-20-26 | Downgrade | Barclays | Overweight → Underweight |
| Apr-15-26 | Downgrade | UBS | Buy → Neutral |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-10-25 | Initiated | Stifel | Buy |
| Sep-10-25 | Initiated | Truist | Buy |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jul-11-25 | Initiated | Raymond James | Outperform |
| Dec-03-24 | Reiterated | BTIG Research | Buy |
| Dec-03-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-22-24 | Initiated | Leerink Partners | Outperform |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-06-24 | Initiated | Stifel | Buy |
| May-30-24 | Initiated | Scotiabank | Sector Perform |
| Mar-21-24 | Initiated | BTIG Research | Buy |
| Mar-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-23 | Initiated | Wedbush | Outperform |
| Nov-14-22 | Initiated | William Blair | Outperform |
View All
Janux Therapeutics Inc Stock (JANX) Latest News
(JANX) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Janux Therapeutics: It's Too Early To Tell If Prostate Cancer Program Can Succeed (JANX) - Seeking Alpha
Here's Why You Should Add JANX Stock to Your Portfolio Now - Eastern Progress
Wall Street Analysts Predict a 155.82% Upside in Janux Therapeutics (JANX): Here's What You Should Know - Eastern Progress
Janux Therapeutics, Inc. (JANX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare ConferenceSlideshow (NASDAQ:JANX) 2026-09-17 - Seeking Alpha
The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and Janux - Yahoo Finance
4 Prostate Cancer Drug Stocks to Watch During Awareness Month - finance.yahoo.com
Janux Therapeutics Doses First Participant in Phase 1 Study of Prostate Cancer Candidate - marketscreener.com
Janux Therapeutics doses first patient in Phase 1 study: Will JANX hold $17.07 support? - Traders Union
Janux doses first patient in JANX013 prostate cancer trial - Investing.com
Janux doses first patient in JANX013 prostate cancer trial By Investing.com - Investing.com Canada
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013 - au.finance.yahoo.com
Price-Driven Insight from (JANX) for Rule-Based Strategy - news.stocktradersdaily.com
Janux’s New Prostate Cancer Combo Trial: What Early Signals Could Mean for JANX - TipRanks
Janux’s JANX014 Prostate Cancer Trial Advances, Keeping Early-Stage Upside in Play - TipRanks
Understanding the Setup: (JANX) and Scalable Risk - Stock Traders Daily
How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44% - qz.com
Wolfe Research Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $23 - Moomoo
Wolfe Research upgrades Janux stock rating on autoimmune data By Investing.com - Investing.com Canada
Wolfe Research upgrades Janux stock rating on autoimmune data - Investing.com
JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know - TradingView
Is Janux Therapeutics (JANX) Narrowing Losses Enough To Shift Its Long-Term Risk Profile? - Sahm
A Quick Look at Today's Ratings for Janux Therapeutics(JANX.US), With a Forecast Between $14 to $60 - Moomoo
Janux (JANX) Latest Quarter: EPS Lands Above Forecast; Market Reaction: Shares Finish 3.30% Higher on the DayEstimate Revision Count - vinanet.vn
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
JANX Q2 2026 Earnings: Narrower-Than-Expected Loss Supports Clinical-Stage ProgressPost-Earnings Drift - dars.gov.et
Dimensional Fund Advisors LP Has $1.34 Million Stake in Janux Therapeutics, Inc. $JANX - MarketBeat
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX) and Ginkgo Bioworks Holdings (DNA) - The Globe and Mail
Point72 reports 3.3% beneficial stake in Janux Therapeutics (JANX) via managed fund - Stock Titan
Janus Henderson Group (JANX) reports 172,229 Janux Therapeutics shares under management - Stock Titan
JANX Stock Edges Up After Hours After Discontinuing Cancer Program In Favor Of Remaining Pipeline - Stocktwits
Stifel Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Janux Therapeutics (JANX) Gains 0.91% as Shares Firmly Hold Above $15.84 SupportHigh Conviction Picks - Vinanet
Equities Analysts Set Expectations for JANX Q3 Earnings - MarketBeat
HC Wainwright Has Negative Outlook of JANX FY2030 Earnings - MarketBeat
Why (JANX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Janux Therapeutics (JANX) Is Up 7.1% After Reporting Narrower Net Losses And Improved Earnings Profile - Yahoo Finance
Janus Living Prices Share Offering - marketscreener.com
Janux Therapeutics Inc (JANX) Stock News Today - TradingKey
RBC Adjusts Price Target on Janux Therapeutics to $34 From $30, Maintains Outperform Rating - Moomoo
Analysts Have Lowered Expectations For Janux Therapeutics, Inc. (NASDAQ:JANX) After Its Latest Results - simplywall.st
Janux Therapeutics (NASDAQ:JANX) Announces Earnings Results - MarketBeat
Bank of America Securities Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX) - The Globe and Mail
Janux Therapeutics Inc (JANX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Janux Therapeutics, Inc. Stock 12‑Month Price Target Cut to $33.25, Implies 107% Upside - TradingView
Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights - BioSpace
JANX Q1 2026 Earnings: Narrower Loss Beats Estimates as Clinical Pipeline Drives FocusRevenue Guidance Update - vinanet.vn
Janux Therapeutics earnings missed by $0.08, revenue fell short of estimates - Investing.com Canada
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Janux Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Janux Therapeutics 2Q 2026: Revenue $10.3M, EPS $(0.35) — 10-Q Summary - TradingView
Janux Therapeutics Inc Stock (JANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):